The Mutations Hiding in Your Blood: How Clonal Hematopoiesis Quietly Drives Heart Disease, and the Rise of Precision Cardio-Hematology

For more than half a century, the story of heart disease has been told in the language of lipids and pressure. Cholesterol clogs arteries, blood pressure strains vessel walls, and the job of prevention is to push those numbers down. That story is real, but it has always left a stubborn gap. A large share of heart attacks happen in people whose cholesterol and blood pressure look acceptable on paper. Something else is at work, and over the past decade a quiet revolution in genomics has revealed one of the strongest hidden contributors yet identified. It does not live in the arteries at all. It lives in the bone marrow.

Presented By Our Partners

The phenomenon is called clonal hematopoiesis of indeterminate potential, or CHIP, and it represents one of the most consequential shifts in how researchers understand the biology of aging and cardiovascular risk. As we age, the blood-forming stem cells in our marrow accumulate random mutations. Most are harmless. But occasionally a mutation gives one stem cell a small competitive edge, allowing it to outgrow its neighbors and produce an expanding family, or clone, of blood cells carrying that same genetic flaw. By the time a person reaches their seventies, this process is remarkably common. And the cells it produces are not neutral bystanders. They actively inflame the arteries from within.

What Clonal Hematopoiesis Actually Is

The concept was crystallized in 2014 and 2015 by researchers including Siddhartha Jaiswal and Benjamin Ebert, working with large genomic datasets that had originally been collected for other purposes. When they sequenced the blood of tens of thousands of people, they found that a meaningful fraction carried somatic mutations, meaning mutations acquired during life rather than inherited, in a small set of genes associated with blood cancers. These people did not have leukemia. They had no abnormal blood counts. Yet they carried an expanding clone of mutated cells. The term clonal hematopoiesis of indeterminate potential was coined to describe exactly this situation, a detectable mutant clone without any diagnosis of blood disease.

The genes involved are a short and revealing list. The two most common are DNMT3A and TET2, followed by ASXL1 and JAK2. These are not random. They are epigenetic regulators, the molecular machinery that controls which genes are switched on and off inside a cell. When they are damaged, the affected stem cells tend to push blood production toward the myeloid lineage, the branch that gives rise to monocytes and macrophages. These are the immune system’s first responders, and when they carry CHIP mutations, they respond too aggressively and for too long.

CHIP is fundamentally a disease of time. It is rare before age 40 and increasingly common with each passing decade, affecting well over 10 percent of people older than 70. This age dependence is part of what makes it such a compelling lens on aging itself. It is a measurable, trackable signature of the slow genetic drift that accumulates in our tissues across a lifetime.

The Inflammation Connection

The link between CHIP and cardiovascular disease was a genuine surprise when it emerged, because the obvious worry about acquiring leukemia-associated mutations would be leukemia. Instead, the dominant danger turned out to be the heart. In Jaiswal’s foundational work published in the New England Journal of Medicine, people with CHIP had roughly a 1.5 to 2 fold increased risk of coronary heart disease, and the risk held up even after accounting for traditional factors. CHIP carriers were also more likely to have early-onset heart attacks. The effect was not subtle, and it was not explained by cholesterol.

The mechanism is now reasonably well mapped, and it runs through inflammation. Mutated myeloid cells that infiltrate the arterial wall produce excess amounts of inflammatory signaling molecules, particularly interleukin-1 beta and interleukin-6. In the case of TET2 mutations, laboratory work has shown that the loss of TET2 activity unleashes the NLRP3 inflammasome, a molecular alarm system inside macrophages that, once triggered, pumps out interleukin-1 beta. This creates a pro-atherogenic environment that accelerates the growth of atherosclerotic plaque and, critically, makes existing plaque more unstable and prone to rupture. A ruptured plaque is what causes most heart attacks.

This places CHIP at the intersection of two of the most important ideas in modern aging science. The first is inflammaging, the concept that chronic low-grade inflammation rises with age and drives much of age-related disease. The second is the recognition that the immune system itself ages and can turn against the body’s own tissues. CHIP is a concrete, sequenceable example of both processes happening at once, which is why a 2026 review in Frontiers in Cardiovascular Medicine described the field as approaching the dawn of precision cardio-hematology.

Featured Partner

Invest in the Infrastructure Behind Modern Medicine

As healthcare expands beyond hospital walls, the buildings and campuses supporting that shift are generating compelling returns for investors who move early. The Healthcare Real Estate Fund offers qualified investors direct access to a curated portfolio of medical office, outpatient, and specialty care facilities.

Learn More →

Reading the Plaque: New Imaging Evidence

Until recently, much of the evidence connecting CHIP to heart disease came from epidemiology and mouse models. That is changing as researchers gain the ability to look directly at the arteries of CHIP carriers using high-resolution imaging. In a study published in August 2025 in Circulation: Cardiovascular Imaging, investigators used optical coherence tomography, a technique that produces detailed cross-sectional images of the inside of coronary arteries, to examine patients who had suffered ST-segment elevation myocardial infarction, the most severe type of heart attack. Patients carrying DNMT3A or TET2 mutations tended to have more severe and more vulnerable plaque. The carriers also had worse prognosis when their heart attack was caused by plaque rupture rather than the gentler mechanism of plaque erosion, and the adverse impact of TET2 mutations was greater than that of DNMT3A.

A companion line of evidence appeared the same month in Genome Medicine, where researchers reported that carrying TET2 or ASXL1 mutations above a variant allele frequency of roughly 0.5 percent was associated with the recognition of vulnerable plaque features in heart attack patients. The variant allele frequency, essentially the size of the mutant clone, matters here. A larger clone means more mutated immune cells circulating and more inflammatory fuel reaching the artery wall. This dose relationship strengthens the case that CHIP is causal rather than merely correlated, and it points toward a future in which clone size becomes a quantifiable risk metric, much like an LDL number is today.

The prognostic weight of CHIP extends beyond the acute event. Analyses published in the European Heart Journal in 2026 examined CHIP and mortality in patients with established coronary artery disease and found that the presence of these mutations tracked with worse long-term outcomes. CHIP is also increasingly implicated in conditions beyond atherosclerosis, including heart failure and atrial fibrillation, where work published in Circulation demonstrated that loss of Tet2 enhances the risk of atrial fibrillation through the same NLRP3 inflammasome pathway.

The Therapeutic Clue Hidden in a Failed Drug Trial

Perhaps the most tantalizing thread in the entire CHIP story comes from a reanalysis of one of cardiology’s most ambitious experiments. The CANTOS trial, conducted from 2011 to 2017 across more than a thousand sites in 39 countries, tested whether canakinumab, a monoclonal antibody that blocks interleukin-1 beta, could reduce cardiovascular events in heart attack survivors who had elevated inflammatory markers. The trial famously proved that targeting inflammation directly, without touching cholesterol, could lower heart attack risk. It was a landmark, though the absolute benefit across the whole population was modest and the drug never became a routine therapy.

Then researchers went back and sequenced the participants for CHIP mutations. The exploratory analysis, later published in JAMA Cardiology, found something striking. Among carriers of TET2-driven clonal hematopoiesis, canakinumab produced a dramatic benefit, with a reduction in major adverse cardiovascular events on the order of 60 percent, far larger than in patients without TET2 mutations who derived little measurable benefit. In other words, the drug that looked only modestly useful for everyone may be powerfully useful for the specific subset of people whose heart risk is being driven by that exact inflammatory mechanism. This is the essence of precision medicine: matching the therapy to the biology rather than treating an averaged population.

This finding has energized interest in anti-inflammatory strategies for CHIP carriers, including colchicine, an inexpensive and long-used anti-inflammatory drug that has independently shown cardiovascular benefit and is now being examined through the lens of clonal hematopoiesis. The vision taking shape is one in which a blood test for CHIP status could one day help identify which patients should receive targeted anti-inflammatory treatment, rather than offering it to everyone or no one.

Why CHIP Reframes the Aging Conversation

What makes clonal hematopoiesis so important to longevity science is that it ties together genomics, immunology, and cardiovascular medicine into a single measurable process. It is not an inherited fate written into your germline at birth. It is something that develops over decades, can be detected with sequencing, can be tracked as it expands, and is mechanistically linked to a treatable pathway. That combination is unusual. Many aging biomarkers tell you that something is changing without telling you what to do about it. CHIP, by contrast, comes attached to a specific molecular mechanism and at least one plausible intervention.

It also reframes heart disease as partly a disorder of the aging immune and blood systems, not solely a plumbing problem of cholesterol and arteries. This has implications well beyond cardiology. The same mutated clones that inflame arteries have been associated with a range of age-related conditions, which raises the possibility that addressing clonal hematopoiesis could yield benefits across multiple organ systems at once. That is the kind of upstream, mechanism-targeting approach that the longevity field has been pursuing across many fronts.

Important caveats remain. CHIP raises relative risk, but most people who carry it will never have a clone-driven heart attack, and routine population-wide screening is not yet recommended outside of research and specialized clinics. The variant allele frequency thresholds that distinguish dangerous clones from trivial ones are still being refined. And while the CANTOS reanalysis is compelling, it was exploratory, meaning it generates a hypothesis rather than proving a treatment strategy. Dedicated prospective trials that enroll CHIP carriers and randomize them to anti-inflammatory therapy are the necessary next step, and several research groups are moving in that direction.

What This Means For You

For most readers, the practical takeaway is not to rush out and demand a CHIP test, which is not yet a standard or widely actionable screen for the general public. The more useful message is about how to think about cardiovascular risk and aging.

First, recognize that heart disease risk is genuinely multifactorial, and that a clean cholesterol panel does not guarantee a clean bill of cardiovascular health. If you have a strong family history of early heart disease, or you have had a cardiac event despite normal lipids, the existence of pathways like CHIP is part of why your physician may take your risk seriously even when the standard numbers look fine.

Second, the CHIP story reinforces, rather than replaces, the value of the lifestyle factors that lower chronic inflammation. The same low-grade inflammatory state that CHIP amplifies is influenced by sleep, physical activity, body composition, and diet. Nothing about this research diminishes the foundational habits that support healthy aging. If anything, it underscores why managing inflammation across your life matters.

Third, if you are someone who already engages with advanced preventive care, this is a topic worth raising with a cardiologist or a preventive medicine specialist, particularly if you are older and have unexplained cardiovascular risk. Some specialized clinics already incorporate clonal hematopoiesis testing into comprehensive risk assessment, and the field is moving quickly. Knowing that mutation-guided anti-inflammatory therapy is on the research horizon can help you and your physician have a more informed conversation about emerging options.

Finally, treat CHIP as a window into how aging biology is being decoded. A decade ago, the idea that mutations in your bone marrow could silently raise your heart attack risk would have sounded improbable. Today it is one of the most active frontiers in cardiovascular medicine, and it is a vivid example of how the tools of genomics are turning the vague concept of aging into specific, measurable, and potentially treatable mechanisms. That shift, from describing aging to acting on it, is what makes this moment in longevity science so consequential.

Free Daily Briefing

The Latest Longevity Science.
Delivered Every Morning.

Join researchers, physicians, and health professionals getting daily breakthroughs in AI-driven medicine, epigenetics, and longevity research.

Support the research that powers this editorial

Subscribe Free

No spam. Unsubscribe anytime. We respect your inbox.